Quinoxalinyl/quinoxalinylakyl-N- terminal cycloalkoxy-C- terminal amino hydroxy .beta.-amino acid derivatives

A pharmaceutical composition comprising a therapeutically-effective amount of a renin-inhibiting compound and a pharmaceutically-acceptable carrier or diluent, said renin-inhibiting compound selected from a family of compounds of the formula ##STR30## wherein R.sub.1 is selected from heteroaryl and heteroaralkyl groups represented by ##STR31## wherein each of Y and Z is independently selected from hydrido, lower alkyl, hydroxy, halo, alkoxy, carboxy, amino, alkylamino, dialkylamino, aryl, sulfhydryl and thioalkyl;

• wherein n is a number selected from zero through five, inclusive;
• wherein each of R.sub.2 and R.sub.4 is independently selected from hydrido and lower alkyl;
• wherein R.sub.3 is selected from hydrido, alkyl, benzyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl and alkylthioalkyl;
• wherein R.sub.5 is selected from cycloalkyl, phenyl, lower alkyl, cycloalkylalkyl and phenylalkyl;
• wherein R.sub.6 and R.sub.7 are taken together to form a partially saturated or fully saturated heterocyclic ring containing five to eight ring members with one or two ring members being oxygen atoms and the remaining ring members being carbon atoms;
• and wherein any of the foregoing R.sub.1 through R.sub.7 substituents having a substitutable position may be substituted with one or more groups selected from alkyl, alkoxy, halo, haloalkyl, alkenyl, alkynyl and cyano;
• or a pharmaceutically-acceptable salt thereof.

A therapeutic method for treating hypertension, said method comprising administering to a hypertensive patient a therapeutically-effective amount of a compound of the formula ##STR32## wherein R.sub.1 is selected from heteroaryl and heteroaralkyl groups represented by ##STR33## wherein each of Y and Z is independently selected from hydrido, lower alkyl, hydroxy, halo, alkoxy, carboxy, amino, alkylamino, dialkylamino, aryl, sulfhydryl and thioalkyl;

• wherein n is a number selected from zero through five, inclusive;
• wherein each of R.sub.2 and R.sub.4 is independently selected from hydrido and lower alkyl;
• wherein R.sub.3 is selected from hydrido, alkyl, benzyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl and alkylthioalkyl;
• wherein R.sub.5 is selected from cycloalkyl, phenyl, lower alkyl, cycloalkylalkyl and phenylalkyl;
• wherein R.sub.6 and R.sub.7 are taken together to form a partially saturated or fully saturated heterocyclic ring containing five to eight ring members with one or two ring members being oxygen atoms and the remaining ring members being carbon atoms;
• and wherein any of the foregoing R.sub.1 through R.sub.7 substituents having a substitutable position may be substituted with one or more groups selected from alkyl, alkoxy, halo, haloalkyl, alkenyl, alkynyl and cyano;
• or a pharmaceutically-acceptable salt thereof.